Sign in Subscribe
Drugs

Genzyme Transgenics Reports 29% Reduction in First Quarter Loss

Strategic Insights

— 1 min read

Genzyme Transgenics Corp. has announced a significant improvement in its financial performance for the first quarter of 1995. The company's net loss for the quarter was $2.3 million, down 29% from the previous quarter's net loss of $3.2 million. This improvement was driven by a 14% increase in service revenues from operations of TSI Corp., a subsidiary acquired in October 1994, and an 11% decrease in operating expenses.

Key Takeaways:

  • The company's total revenues for the first quarter of 1995 were $8.8 million, a significant increase from the $722,000 reported in the first quarter of 1994. Of this increase, $7.7 million was due to the inclusion of TSI Corp.'s operations.
  • Service revenues increased to $7.7 million from $6.7 million in the previous quarter, while the gross margin on services rose to 14.2% from 1.3% in the prior quarter.
  • Total operating expenses decreased to $11.0 million from $12.3 million in the previous quarter.
  • The company has made significant progress in expanding its capacity for transgenic production, including the completion of a new facility in central Massachusetts and the successful completion of the first transgenic procedures there.
  • Preclinical research on the company's lead product, human recombinant antithrombin III (AT-III), continued on schedule, with plans to file an IND by the end of the year, making AT-III the world's first transgenic product to enter clinical trials.

Statistics:

  • The company's net loss for the first quarter of 1995 was $2.3 million, a reduction of 29% from the previous quarter's net loss of $3.2 million. (Source: Genzyme Transgenics, 1995 Q1 Earnings Report)
  • Total revenues for the first quarter of 1995 were $8.8 million, a 1,201% increase from the $722,000 reported in the first quarter of 1994. (Source: Genzyme Transgenics, 1995 Q1 Earnings Report)
  • Service revenues increased to $7.7 million from $6.7 million in the previous quarter, representing a growth of 15%. (Source: Genzyme Transgenics, 1995 Q1 Earnings Report)
  • The gross margin on services rose to 14.2% from 1.3% in the prior quarter, representing a significant improvement. (Source: Genzyme Transgenics, 1995 Q1 Earnings Report)

Sources:

  • Genzyme Transgenics, 1995 Q1 Earnings Report (April 26, 1995)
  • Genzyme Transgenics, Press Release (April 26, 1995)

Read more